Endothelial NADPH oxidases: Which NOX to target in vascular disease?

Trends in Endocrinology and Metabolism

Volumn 25, Issue 9, 2014, Pages 452-463

  Drummond, Grant R ^a   Sobey, Christopher G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Diabetes; Endothelial dysfunction; Hyperlipidemia; Hypertension; Inflammation; NADPH oxidases; Reactive oxygen species; Selective NOX1 2 inhibitors; Vascular disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; APOCYNIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; SUPEROXIDE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CARDIOVASCULAR AGENT; CYBB PROTEIN, HUMAN; ENZYME INHIBITOR; MEMBRANE PROTEIN; NOX1 PROTEIN, HUMAN; NOX4 PROTEIN, HUMAN; NOX5 PROTEIN, HUMAN;

APOPTOSIS; ATHEROSCLEROSIS; BIOAVAILABILITY; BLOOD CLOTTING; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS MEMBRANE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ELECTRON TRANSPORT; ENDOPLASMIC RETICULUM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE DELETION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; TRANSGENIC MOUSE; VASCULAR DISEASES; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR AGENTS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NADPH OXIDASE; VASCULAR DISEASES;

EID: 84906794864     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.06.012     Document Type: Review

References (130)

1. Drummond G.R., et al. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 2011, 10:453-471.
2. Lassegue B., et al. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ. Res. 2012, 110:1364-1390.
3. Nishino T., et al. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008, 275:3278-3289.
4. Lei H., et al. Molecular mechanisms of endothelial NO synthase uncoupling. Curr. Pharm. Des. 2014, 20:3548-3553.
5. Montezano A.C., Touyz R.M. Reactive oxygen species and endothelial function - role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases. Basic Clin. Pharmacol. Toxicol. 2012, 110:87-94.
6. de Oliveira-Junior E.B., et al. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand. J. Immunol. 2011, 73:420-427.
7. Wingler K., et al. NOX1, 2, 4, 5: counting out oxidative stress. Br. J. Pharmacol. 2011, 164:866-883.
8. Takac I., et al. The Nox family of NADPH oxidases: friend or foe of the vascular system?. Curr. Hypertens. Rep. 2012, 14:70-78.
9. Antoniades C., et al. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J. Am. Coll. Cardiol. 2008, 52:158-165.
10. Arruda M.A., Barja-Fidalgo C. NADPH oxidase activity: In the crossroad of neutrophil life and death. Front. Biosci. (Elite Ed.) 2009, 14:4546-4556.
11. Dharmarajah J., et al. The anti-platelet effects of apocynin in mice are not mediated by inhibition of NADPH oxidase activity. Naunyn Schmiedebergs Arch Pharmacol. 2010, 382:377-384.
12. Violi F., Pignatelli P. Platelet oxidative stress and thrombosis. Thromb. Res. 2012, 129:378-381.
13. Fan L.M., et al. Knockout of p47 phox uncovers a critical role of p40 phox in reactive oxygen species production in microvascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1651-1656.
14. Opitz N., et al. The 'A's and 'O's of NADPH oxidase regulation: a commentary on 'Subcellular localization and function of alternatively spliced Noxo1 isoforms'. Free Radic. Biol. Med. 2007, 42:175-179.
15. Laurindo F.R., et al. Novel role of protein disulfide isomerase in the regulation of NADPH oxidase activity: pathophysiological implications in vascular diseases. Antioxid. Redox Signal. 2008, 10:1101-1113.
16. Ambasta R.K., et al. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J. Biol. Chem. 2004, 279:45935-45941.
17. Miyano K., et al. Direct involvement of the small GTPase Rac in activation of the superoxide-producing NADPH oxidase Nox1. J. Biol. Chem. 2006, 281:21857-21868.
18. Banfi B., et al. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J. Biol. Chem. 2003, 278:3510-3513.
19. Takeya R., et al. Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J. Biol. Chem. 2003, 278:25234-25246.
20. Ago T., et al. NAD(P)H oxidases in rat basilar arterial endothelial cells. Stroke 2005, 36:1040-1046.
21. Honjo T., et al. Essential role of NOXA1 in generation of reactive oxygen species induced by oxidized low-density lipoprotein in human vascular endothelial cells. Endothelium 2008, 15:137-141.
22. Ambasta R.K., et al. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic. Biol. Med. 2006, 41:193-201.
23. Martyn K.D., et al. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell. Signal. 2006, 18:69-82.
24. Lyle A.N., et al. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ. Res. 2009, 105:249-259.
25. Sutliff R.L., et al. Polymerase delta interacting protein 2 sustains vascular structure and function. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2154-2161.
26. 2+ activation of the NADPH oxidase 5 (NOX5). J. Biol. Chem. 2004, 279:18583-18591.
27. BelAiba R.S., et al. NOX5 variants are functionally active in endothelial cells. Free Radic. Biol. Med. 2007, 42:446-459.
28. Wind S., et al. Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 2010, 56:490-497.
29. Paravicini T.M., et al. Increased NADPH oxidase activity, gp91phox expression, and endothelium-dependent vasorelaxation during neointima formation in rabbits. Circ. Res. 2002, 91:54-61.
30. -/- mice. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H24-H32.
31. Niu X.L., et al. Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 2010, 121:549-559.
32. Wendt M.C., et al. Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radic. Biol. Med. 2005, 39:381-391.
33. Roberts C.K., et al. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 2006, 55:928-934.
34. Tajbakhsh N., Sokoya E.M. Sirtuin 1 is upregulated in young obese Zucker rat cerebral arteries. Eur. J. Pharmacol. 2013, 721:43-48.
35. Huang A., et al. Exacerbation of endothelial dysfunction during the progression of diabetes: role of oxidative stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302:R674-R681.
36. Guzik T.J., et al. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:333-339.
37. Guzik T.J., et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 2008, 52:1803-1809.
38. Chen C.Y., et al. Inhibitory effect of delphinidin on monocyte-endothelial cell adhesion induced by oxidized low-density lipoprotein via ROS/p38MAPK/NF-kappaB pathway. Cell Biochem. Biophys. 2011, 61:337-348.
39. Dandapat A., et al. Small concentrations of oxLDL induce capillary tube formation from endothelial cells via LOX-1-dependent redox-sensitive pathway. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2435-2442.
40. Shin H.K., et al. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004, 109:1022-1028.
41. Zhao R., et al. Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E104-E111.
42. Stielow C., et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem. Biophys. Res. Commun. 2006, 344:200-205.
43. Rouhanizadeh M., et al. Oxidized-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine induces vascular endothelial superoxide production: implication of NADPH oxidase. Free Radic. Biol. Med. 2005, 39:1512-1522.
44. Bismuth J., et al. Lactosylceramide causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Med. Sci. Monit. 2009, 15:BR270-BR274.
45. Jawien J., et al. Mouse models of experimental atherosclerosis. J. Physiol. Pharmacol. 2004, 55:503-517.
46. Getz G.S., Reardon C.A. Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1104-1115.
47. Bond A.R., Jackson C.L. The fat-fed apolipoprotein E knockout mouse brachiocephalic artery in the study of atherosclerotic plaque rupture. J. Biomed. Biotechnol. 2011, 2011:379069.
48. -/- mice. J. Clin. Invest. 2001, 108:1513-1522.
49. Vendrov A.E., et al. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2714-2721.
50. Kirk E.A., et al. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1529-1535.
51. Hsich E., et al. Vascular effects following homozygous disruption of p47(phox): an essential component of NADPH oxidase. Circulation 2000, 101:1234-1236.
52. Montezano A.C., Touyz R.M. Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann. Med. 2012, 44(Suppl. 1):S2-S16.
53. Rueckschloss U., et al. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1845-1851.
54. Li J.M., Shah A.M. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J. Biol. Chem. 2003, 278:12094-12100.
55. Gavazzi G., et al. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 2007, 50:189-196.
56. Matsuno K., et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005, 112:2677-2685.
57. Wang H.D., et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ. Res. 2001, 88:947-953.
58. Serrander L., et al. NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem. J. 2007, 406:105-114.
59. Carlstrom M., et al. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R72-R79.
60. Loot A.E., et al. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J. Exp. Med. 2009, 206:2889-2896.
61. Landmesser U., et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
62. Landmesser U., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 2003, 111:1201-1209.
63. Schroder K., et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ. Res. 2012, 110:1217-1225.
64. Chen F., et al. Resveratrol protects vascular endothelial cells from high glucose-induced apoptosis through inhibition of NADPH oxidase activation-driven oxidative stress. CNS Neurosci. Ther. 2013, 19:675-681.
65. Taye A., et al. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur. J. Pharmacol. 2010, 627:42-48.
66. Williams C.R., et al. Rosiglitazone attenuates NF-kappaB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cells. Am. J. Physiol. Cell Physiol. 2012, 303:C213-C223.
67. Chen F., et al. Regulation of NADPH oxidase 5 by protein kinase C isoforms. PLoS ONE 2014, 9:e88405.
68. Lynch C.M., et al. Nox2-derived superoxide contributes to cerebral vascular dysfunction in diet-induced obesity. Stroke 2013, 44:3195-3201.
69. Du J., et al. Crucial roles of Nox2-derived oxidative stress in deteriorating the function of insulin receptors and endothelium in dietary obesity of middle-aged mice. Br. J. Pharmacol. 2013, 170:1064-1077.
70. Sukumar P., et al. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 2013, 62:2130-2134.
71. Youn J.Y., et al. The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes. Diabetologia 2012, 55:2069-2079.
72. Gray S.P., et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 2013, 127:1888-1902.
73. Bendall J.K., et al. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: studies in endothelial-targeted Nox2 transgenic mice. Circ. Res. 2007, 100:1016-1025.
74. Murdoch C.E., et al. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res. Cardiol. 2011, 106:527-538.
75. -/- mice. Cardiovasc. Res. 2012, 94:20-29.
76. Ray R., et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1368-1376.
77. Thomas S.R., et al. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2008, 10:1713-1765.
78. Qian J., Fulton D. Post-translational regulation of endothelial nitric oxide synthase in vascular endothelium. Front. Physiol. 2013, 4:347.
79. Bayraktutan U., et al. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1903-1911.
80. Li J.M., Shah A.M. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J. Biol. Chem. 2002, 277:19952-19960.
81. Kuroda J., et al. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 2005, 10:1139-1151.
82. Van Buul J.D., et al. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid. Redox Signal. 2005, 7:308-317.
83. Anilkumar N., et al. A 28-kDa splice variant of NADPH oxidase-4 is nuclear-localized and involved in redox signaling in vascular cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33:e104-e112.
84. Nauseef W.M. Detection of superoxide anion and hydrogen peroxide production by cellular NADPH oxidases. Biochim. Biophys. Acta 2014, 1840:757-767.
85. Fukai T., Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal. 2011, 15:1583-1606.
86. Zhang A.Y., et al. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Hypertension 2006, 47:74-80.
87. Jin S., et al. Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 2008, 28:485-490.
88. Wei Y.M., et al. Attenuation by statins of membrane raft-redox signaling in coronary arterial endothelium. J. Pharmacol. Exp. Ther. 2013, 345:170-179.
89. Boini K.M., et al. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim. Biophys. Acta 2010, 1801:1294-1304.
90. Woods A.A., et al. Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem. J. 2003, 370:729-735.
91. Oliveira-Marques V., et al. Role of hydrogen peroxide in NF-kappaB activation: from inducer to modulator. Antioxid. Redox Signal. 2009, 11:2223-2243.
92. Son Y., et al. Reactive oxygen species in the activation of MAP kinases. Methods Enzymol. 2013, 528:27-48.
93. Montezano A.C., et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ. Res. 2010, 106:1363-1373.
94. Ning R.B., et al. RXR agonists inhibit high glucose-induced upregulation of inflammation by suppressing activation of the NADPH oxidase-nuclear factor-kappaB pathway in human endothelial cells. Genet. Mol. Res. 2013, 12:6692-6707.
95. Xia F., et al. Luteolin protects HUVECs from TNF-alpha-induced oxidative stress and inflammation via its effects on the Nox4/ROS-NF-kappaB and MAPK pathways. J. Atheroscler. Thromb. 2014.
96. Sorescu G.P., et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ. Res. 2004, 95:773-779.
97. Hwang J., et al. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ. Res. 2003, 93:1225-1232.
98. White S.J., et al. Characterization of the differential response of endothelial cells exposed to normal and elevated laminar shear stress. J. Cell. Physiol. 2011, 226:2841-2848.
99. Xiao H., et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 2013, 128:632-642.
100. Dikalov S.I., et al. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic. Biol. Med. 2008, 45:1340-1351.
101. Takac I., et al. The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J. Biol. Chem. 2011, 286:13304-13313.
102. Drummond G.R., et al. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ. Res. 2000, 86:347-354.
103. Thomas S.R., et al. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J. Biol. Chem. 2002, 277:6017-6024.
104. Breton-Romero R., et al. Critical role of hydrogen peroxide signaling in the sequential activation of p38 MAPK and eNOS in laminar shear stress. Free Radic. Biol. Med. 2012, 52:1093-1100.
105. Craige S.M., et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011, 124:731-740.
106. Paravicini T.M., et al. Flow-induced cerebral vasodilatation in vivo involves activation of phosphatidylinositol-3 kinase, NADPH-oxidase, and nitric oxide synthase. J. Cereb. Blood Flow Metab. 2006, 26:836-845.
107. Matoba T., et al. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1224-1230.
108. - and systolic blood pressure in mice. Circ. Res. 2001, 89:408-414.
109. Ranayhossaini D.J., et al. Selective recapitulation of conserved and nonconserved regions of putative NOXA1 protein activation domain confers isoform-specific inhibition of Nox1 oxidase and attenuation of endothelial cell migration. J. Biol. Chem. 2013, 288:36437-36450.
110. Gianni D., et al. A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem. Biol. 2010, 5:981-993.
111. Selemidis S., et al. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol. Ther. 2008, 120:254-291.
112. Stolk J., et al. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am. J. Respir. Cell Mol. Biol. 1994, 11:95-102.
113. Van den Worm E., et al. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Eur. J. Pharmacol. 2001, 433:225-230.
114. Ellmark S.H., et al. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc. Res. 2005, 65:495-504.
115. Serrander L., et al. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 2007, 89:1159-1167.
116. Hu L., et al. Apocynin but not L-arginine prevents and reverses dexamethasone-induced hypertension in the rat. Am. J. Hypertens. 2006, 19:413-418.
117. Baumer A.T., et al. The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade. Clin. Exp. Hypertens. 2007, 29:287-299.
118. Virdis A., et al. Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension 2007, 49:679-686.
119. Kinkade K., et al. Inhibition of NADPH oxidase by apocynin attenuates progression of atherosclerosis. Int. J. Mol. Sci. 2013, 14:17017-17028.
120. Heumuller S., et al. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008, 51:211-217.
121. Stolk J., et al. Apocynin improves the efficacy of secretory leukocyte protease inhibitor in experimental emphysema. Am. J. Respir. Crit. Care Med. 1994, 150:1628-1631.
122. Ximenes V.F., et al. The oxidation of apocynin catalyzed by myeloperoxidase: proposal for NADPH oxidase inhibition. Arch. Biochem. Biophys. 2007, 457:134-141.
123. Anatoliotakis N., et al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Curr. Top. Med. Chem. 2013, 13:115-138.
124. Petronio M.S., et al. Apocynin: chemical and biophysical properties of a NADPH oxidase inhibitor. Molecules 2013, 18:2821-2839.
125. Holland S.M. Chronic granulomatous disease. Hematol. Oncol. Clin. North Am. 2013, 27:89-99.
126. Kuhns D.B., et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 2010, 363:2600-2610.
127. Peters E.A., et al. Effect of apocynin on ozone-induced airway hyperresponsiveness to methacholine in asthmatics. Free Radic. Biol. Med. 2001, 31:1442-1447.
128. Stefanska J., et al. Apocynin decreases hydrogen peroxide and nitrate concentrations in exhaled breath in healthy subjects. Pulm. Pharmacol. Ther. 2010, 23:48-54.
129. Stefanska J., et al. Apocynin reduces reactive oxygen species concentrations in exhaled breath condensate in asthmatics. Exp. Lung Res. 2012, 38:90-99.
130. Rehder D.S., Borges C.R. Cysteine sulfenic acid as an intermediate in disulfide bond formation and nonenzymatic protein folding. Biochemistry 2010, 49:7748-7755.